Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):153-60

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  MIBG IN THE DIAGNOSIS AND THERAPY OF PHEOCHROMOCYTHOMA AND PARAGANGLIOMA


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):153-60

language: English

Malignant pheochromocytoma and paraganglioma: future considerations for therapy

Buzzoni R. 1, Pusceddu S. 2, Damato A. 1, Meroni E. 3, Aktolun C. 4, Milione M. 5, Mazzaferro V. 6, De Braud F. 2, Spreafico C. 7, Maccauro M. 8, Zaffaroni N. 9, Castellani M. R. 8

1 Day Hospital Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
2 Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
3 Endoscopy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
4 Molecular Imaging Program at Stanford (MIPS) Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA;
5 Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
6 Surgery and Liver Transplantation Unit Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy;
7 Radiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
8 Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
9 Molecular Pharmacology Unit Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy


PDF  REPRINTS


Pheochromocytoma and paraganglioma are rare neuroendocrine tumors. Knowledge about such neoplasms ameliorated in the last 10-15 years with the discovery of increasing number of germ line mutations even in apparently sporadic cases. Seemingly, genetic tests are going to be an integral part of diagnostic procedures. Standard therapies (advanced surgery, radiometabolic therapy, chemotherapy and radiotherapy) have revealed suboptimal results in tumor size reduction and survival. Currently, there is no standard therapeutic protocol and thus some patients end up with overtreatment while others are undertreated. An effective molecular target therapy aiming at permanent control of these highly complex neoplasms should be the aim of future efforts. In clinical setting investigatory trials with multiple drug therapies targeting a variety of different parallel pathways should be available. Successful management requires a multidisciplinary teamwork.

top of page